Gilead Says Covid Drug Remdesivir Shows Antiviral Activity against Omicron

103
8
Favorite

Gilead Says Covid Drug Remdesivir Shows Antiviral Activity against Omicron

Yahoo Finance2022-02-11

(Reuters) - Gilead Sciences Inc's drug, remdesivir, showed antiviral activity against Omicron, Delta and other variants of the coronavirus in laboratory studies, the company said on Friday.

The study results showed similar activity of remdesivir against the variants and an early ancestral strain of the virus detected in Seattle, Washington, Gilead said.

Remdesivir, marketed as Veklury, was approved by the FDA in October 2020 to treat hospitalized COVID-19 patients. Last month, this was expanded to non-hospitalized patients who were at high risk of severe disease.

Gilead added that the viral enzyme of the coronavirus that remdesivir targets does not contain any additional unique mutations.

"Now with a new version of Omicron (BA.2 subvariant) increasing in circulation around the world, these latest data also suggest that remdesivir will retain antiviral activity against this new subvariant," said Tomas Cihlar, senior vice president of virology research at Gilead.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

103

Report

Comment（8）

SSVC
·2022-02-13
K
Reply
2
Report
akhwe
·2022-02-12
Great
Reply
1
Report
Fold Replies
- wywy:
  yea. happy investing
  2022-02-12
  Reply
  Report
lin2993
·2022-02-12
How many vaccines we need
Reply
2
Report
Fold Replies
- wywy:
  yea. happy investing
  2022-02-12
  Reply
  Report
MHh
·2022-02-11
Drug so expensive! Not cost effective against vaccines, not considering the mortality or morbidity risk with infection
Reply
7
Report
Ah Deck
·2022-02-11
Hope we do not need to take 4th jab 😤..plslike
Reply
2
Report
JohanS
·2022-02-11
Nice please like
Reply
5
Report
Fold Replies
- Meeooww:
  ok
  2022-02-11
  Reply
  Report
JiaocyTi
·2022-02-11
23
Reply
3
Report
Fold Replies
- JiaocyTi:
  123
  2022-02-11
  Reply
  Report
zero79
·2022-02-11
Cool
Reply
4
Report
Fold Replies
- ATJS:
  yeah
  2022-02-11
  Reply
  Report

7x24

All

22:45
Kugler: Facing Potential Shocks NOW, Much Related to Tariffs and Uncertainty
22:41
Exclusive-Conocophillips Says It Has Informed Employees That Workforce Reductions Are Anticipated
22:38
Elon Musk discussed Tesla's progress on autonomous driving and future plans. Key points:1. Tesla aims to offer paid fully autonomous rides in Austin by June, expanding to other U.S. cities by year-end.2. Expects millions of Teslas operating autonomously in the second half of 2025.3. Personal use of unsupervised FSD expected in several U.S. cities by end of 2024.4. Tesla's approach uses AI and cameras, which they believe is superior to competitors' more expensive sensor suites.5. All current Model Y vehicles are capable of autonomous driving, already used in factory operations.6. Tesla is developing a revolutionary "unboxed" production system for Cybertruck, aiming for a 5-second production cycle time per vehicle.Disclaimer: This earnings call summary is generated by AI and is for informational purposes only. Due to technical limitations, inaccuracies may exist. It does not constitute investment advice or commitments.
22:38
Brazil's Totvs: Lazard Reached a 5.02% Stake of Totvs - Filing
22:38
Enlitic Inc - Secures Migration & Ensight Agreements With Estimated Total Contract Value of a$2.5M in Revenue

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1128194114?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2022-02-11 22:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128194114","market":"us","top_or_hot":-1,"title":"Gilead Says Covid Drug Remdesivir Shows Antiviral Activity against Omicron","media":"Yahoo Finance","content":"<html><head></head><body><p>(Reuters) - <a href=\"https://laohu8.com/S/GILD\">Gilead Sciences Inc</a>&#39;s drug, remdesivir, showed antiviral activity against Omicron, Delta and other variants of the coronavirus in laboratory studies, the company said on Friday.</p><p>The study results showed similar activity of remdesivir against the variants and an early ancestral strain of the virus detected in Seattle, Washington, Gilead said.</p><p>Remdesivir, marketed as Veklury, was approved by the FDA in October 2020 to treat hospitalized COVID-19 patients. Last month, this was expanded to non-hospitalized patients who were at high risk of severe disease.</p><p>Gilead added that the viral enzyme of the coronavirus that remdesivir targets does not contain any additional unique mutations.</p><p>&#34;Now with a new version of Omicron (BA.2 subvariant) increasing in circulation around the world, these latest data also suggest that remdesivir will retain antiviral activity against this new subvariant,&#34; said Tomas Cihlar, senior vice president of virology research at Gilead.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Says Covid Drug Remdesivir Shows Antiviral Activity against Omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Says Covid Drug Remdesivir Shows Antiviral Activity against Omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-11 22:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/gilead-says-covid-drug-remdesivir-135752475.html><strong>Yahoo Finance</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) - Gilead Sciences Inc's drug, remdesivir, showed antiviral activity against Omicron, Delta and other variants of the coronavirus in laboratory studies, the company said on Friday.The study ...</p>\n\n<a href=\"https://finance.yahoo.com/news/gilead-says-covid-drug-remdesivir-135752475.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GILD","symbol_name":"吉利德科学","start_time":0,"source_url":"https://finance.yahoo.com/news/gilead-says-covid-drug-remdesivir-135752475.html","article_id":"1128194114","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128194114","pubTimestamp":1644588396,"columns":[],"sourceInfo":null,"weMediaInfo":null,"summary":"(Reuters) - Gilead Sciences Inc's drug, remdesivir, showed antiviral activity against Omicron, Delta","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"GILD":"吉利德科学"},"translate_title":"Gilead说Covid药物Remdesivir显示出对奥密克戎病毒的抗病毒活性","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GILD":0.9},"content_text":"(Reuters) - Gilead Sciences Inc's drug, remdesivir, showed antiviral activity against Omicron, Delta and other variants of the coronavirus in laboratory studies, the company said on Friday.The study results showed similar activity of remdesivir against the variants and an early ancestral strain of the virus detected in Seattle, Washington, Gilead said.Remdesivir, marketed as Veklury, was approved by the FDA in October 2020 to treat hospitalized COVID-19 patients. Last month, this was expanded to non-hospitalized patients who were at high risk of severe disease.Gilead added that the viral enzyme of the coronavirus that remdesivir targets does not contain any additional unique mutations.\"Now with a new version of Omicron (BA.2 subvariant) increasing in circulation around the world, these latest data also suggest that remdesivir will retain antiviral activity against this new subvariant,\" said Tomas Cihlar, senior vice president of virology research at Gilead.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"},"commentList":[{"id":9092730656,"gmtCreate":1644724956251,"gmtModify":1676533956935,"author":{"id":"3574906731000207","authorId":"3574906731000207","name":"SSVC","avatar":"https://static.tigerbbs.com/545a5ea462ff4ac7cc100bd3d8d97f72","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3574906731000207","authorIdStr":"3574906731000207"},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9092730656","repostId":1128194114,"repostType":4,"repost":{"id":"1128194114","kind":"news","pubTimestamp":1644588396,"share":"https://ttm.financial/m/news/1128194114?lang=&edition=full_marsco","pubTime":"2022-02-11 22:06","market":"us","language":"en","title":"Gilead Says Covid Drug Remdesivir Shows Antiviral Activity against Omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=1128194114","media":"Yahoo Finance","summary":"(Reuters) - Gilead Sciences Inc's drug, remdesivir, showed antiviral activity against Omicron, Delta","content":"<html><head></head><body><p>(Reuters) - <a href=\"https://laohu8.com/S/GILD\">Gilead Sciences Inc</a>&#39;s drug, remdesivir, showed antiviral activity against Omicron, Delta and other variants of the coronavirus in laboratory studies, the company said on Friday.</p><p>The study results showed similar activity of remdesivir against the variants and an early ancestral strain of the virus detected in Seattle, Washington, Gilead said.</p><p>Remdesivir, marketed as Veklury, was approved by the FDA in October 2020 to treat hospitalized COVID-19 patients. Last month, this was expanded to non-hospitalized patients who were at high risk of severe disease.</p><p>Gilead added that the viral enzyme of the coronavirus that remdesivir targets does not contain any additional unique mutations.</p><p>&#34;Now with a new version of Omicron (BA.2 subvariant) increasing in circulation around the world, these latest data also suggest that remdesivir will retain antiviral activity against this new subvariant,&#34; said Tomas Cihlar, senior vice president of virology research at Gilead.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Says Covid Drug Remdesivir Shows Antiviral Activity against Omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Says Covid Drug Remdesivir Shows Antiviral Activity against Omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-11 22:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/gilead-says-covid-drug-remdesivir-135752475.html><strong>Yahoo Finance</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) - Gilead Sciences Inc's drug, remdesivir, showed antiviral activity against Omicron, Delta and other variants of the coronavirus in laboratory studies, the company said on Friday.The study ...</p>\n\n<a href=\"https://finance.yahoo.com/news/gilead-says-covid-drug-remdesivir-135752475.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学"},"source_url":"https://finance.yahoo.com/news/gilead-says-covid-drug-remdesivir-135752475.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128194114","content_text":"(Reuters) - Gilead Sciences Inc's drug, remdesivir, showed antiviral activity against Omicron, Delta and other variants of the coronavirus in laboratory studies, the company said on Friday.The study results showed similar activity of remdesivir against the variants and an early ancestral strain of the virus detected in Seattle, Washington, Gilead said.Remdesivir, marketed as Veklury, was approved by the FDA in October 2020 to treat hospitalized COVID-19 patients. Last month, this was expanded to non-hospitalized patients who were at high risk of severe disease.Gilead added that the viral enzyme of the coronavirus that remdesivir targets does not contain any additional unique mutations.\"Now with a new version of Omicron (BA.2 subvariant) increasing in circulation around the world, these latest data also suggest that remdesivir will retain antiviral activity against this new subvariant,\" said Tomas Cihlar, senior vice president of virology research at Gilead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9092250402,"gmtCreate":1644638047919,"gmtModify":1676533949886,"author":{"id":"3581422628246899","authorId":"3581422628246899","name":"akhwe","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":1,"idStr":"3581422628246899","authorIdStr":"3581422628246899"},"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9092250402","repostId":1128194114,"repostType":4,"repost":{"id":"1128194114","kind":"news","pubTimestamp":1644588396,"share":"https://ttm.financial/m/news/1128194114?lang=&edition=full_marsco","pubTime":"2022-02-11 22:06","market":"us","language":"en","title":"Gilead Says Covid Drug Remdesivir Shows Antiviral Activity against Omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=1128194114","media":"Yahoo Finance","summary":"(Reuters) - Gilead Sciences Inc's drug, remdesivir, showed antiviral activity against Omicron, Delta","content":"<html><head></head><body><p>(Reuters) - <a href=\"https://laohu8.com/S/GILD\">Gilead Sciences Inc</a>&#39;s drug, remdesivir, showed antiviral activity against Omicron, Delta and other variants of the coronavirus in laboratory studies, the company said on Friday.</p><p>The study results showed similar activity of remdesivir against the variants and an early ancestral strain of the virus detected in Seattle, Washington, Gilead said.</p><p>Remdesivir, marketed as Veklury, was approved by the FDA in October 2020 to treat hospitalized COVID-19 patients. Last month, this was expanded to non-hospitalized patients who were at high risk of severe disease.</p><p>Gilead added that the viral enzyme of the coronavirus that remdesivir targets does not contain any additional unique mutations.</p><p>&#34;Now with a new version of Omicron (BA.2 subvariant) increasing in circulation around the world, these latest data also suggest that remdesivir will retain antiviral activity against this new subvariant,&#34; said Tomas Cihlar, senior vice president of virology research at Gilead.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Says Covid Drug Remdesivir Shows Antiviral Activity against Omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Says Covid Drug Remdesivir Shows Antiviral Activity against Omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-11 22:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/gilead-says-covid-drug-remdesivir-135752475.html><strong>Yahoo Finance</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) - Gilead Sciences Inc's drug, remdesivir, showed antiviral activity against Omicron, Delta and other variants of the coronavirus in laboratory studies, the company said on Friday.The study ...</p>\n\n<a href=\"https://finance.yahoo.com/news/gilead-says-covid-drug-remdesivir-135752475.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学"},"source_url":"https://finance.yahoo.com/news/gilead-says-covid-drug-remdesivir-135752475.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128194114","content_text":"(Reuters) - Gilead Sciences Inc's drug, remdesivir, showed antiviral activity against Omicron, Delta and other variants of the coronavirus in laboratory studies, the company said on Friday.The study results showed similar activity of remdesivir against the variants and an early ancestral strain of the virus detected in Seattle, Washington, Gilead said.Remdesivir, marketed as Veklury, was approved by the FDA in October 2020 to treat hospitalized COVID-19 patients. Last month, this was expanded to non-hospitalized patients who were at high risk of severe disease.Gilead added that the viral enzyme of the coronavirus that remdesivir targets does not contain any additional unique mutations.\"Now with a new version of Omicron (BA.2 subvariant) increasing in circulation around the world, these latest data also suggest that remdesivir will retain antiviral activity against this new subvariant,\" said Tomas Cihlar, senior vice president of virology research at Gilead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":100513013,"gmtCreate":1644670830872,"gmtModify":1663243682632,"authorId":3566982670449095,"author":{"id":3566982670449095,"idStr":"3566982670449095","authorId":3566982670449095,"name":"wywy","avatar":"https://static.tigerbbs.com/76ed86374fc7b16c12094c45ea30787c","vip":2,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.82%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":6,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9092250402,"type":1,"supId":0,"prevId":0,"content":"yea. happy <u>investing</u>","text":"yea. happy <u>investing</u>","html":"yea. happy <u>investing</u>"}],"langContent":"EN"},{"id":9092622555,"gmtCreate":1644624586005,"gmtModify":1676533946785,"author":{"id":"3582016232312277","authorId":"3582016232312277","name":"lin2993","avatar":"https://static.tigerbbs.com/440bbfcba36c9b9dbee0fd014341c65e","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":6,"crmLevelSwitch":0,"idStr":"3582016232312277","authorIdStr":"3582016232312277"},"htmlText":"How many vaccines we need","listText":"How many vaccines we need","text":"How many vaccines we need","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9092622555","repostId":1128194114,"repostType":4,"repost":{"id":"1128194114","kind":"news","pubTimestamp":1644588396,"share":"https://ttm.financial/m/news/1128194114?lang=&edition=full_marsco","pubTime":"2022-02-11 22:06","market":"us","language":"en","title":"Gilead Says Covid Drug Remdesivir Shows Antiviral Activity against Omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=1128194114","media":"Yahoo Finance","summary":"(Reuters) - Gilead Sciences Inc's drug, remdesivir, showed antiviral activity against Omicron, Delta","content":"<html><head></head><body><p>(Reuters) - <a href=\"https://laohu8.com/S/GILD\">Gilead Sciences Inc</a>&#39;s drug, remdesivir, showed antiviral activity against Omicron, Delta and other variants of the coronavirus in laboratory studies, the company said on Friday.</p><p>The study results showed similar activity of remdesivir against the variants and an early ancestral strain of the virus detected in Seattle, Washington, Gilead said.</p><p>Remdesivir, marketed as Veklury, was approved by the FDA in October 2020 to treat hospitalized COVID-19 patients. Last month, this was expanded to non-hospitalized patients who were at high risk of severe disease.</p><p>Gilead added that the viral enzyme of the coronavirus that remdesivir targets does not contain any additional unique mutations.</p><p>&#34;Now with a new version of Omicron (BA.2 subvariant) increasing in circulation around the world, these latest data also suggest that remdesivir will retain antiviral activity against this new subvariant,&#34; said Tomas Cihlar, senior vice president of virology research at Gilead.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Says Covid Drug Remdesivir Shows Antiviral Activity against Omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Says Covid Drug Remdesivir Shows Antiviral Activity against Omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-11 22:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/gilead-says-covid-drug-remdesivir-135752475.html><strong>Yahoo Finance</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) - Gilead Sciences Inc's drug, remdesivir, showed antiviral activity against Omicron, Delta and other variants of the coronavirus in laboratory studies, the company said on Friday.The study ...</p>\n\n<a href=\"https://finance.yahoo.com/news/gilead-says-covid-drug-remdesivir-135752475.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学"},"source_url":"https://finance.yahoo.com/news/gilead-says-covid-drug-remdesivir-135752475.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128194114","content_text":"(Reuters) - Gilead Sciences Inc's drug, remdesivir, showed antiviral activity against Omicron, Delta and other variants of the coronavirus in laboratory studies, the company said on Friday.The study results showed similar activity of remdesivir against the variants and an early ancestral strain of the virus detected in Seattle, Washington, Gilead said.Remdesivir, marketed as Veklury, was approved by the FDA in October 2020 to treat hospitalized COVID-19 patients. Last month, this was expanded to non-hospitalized patients who were at high risk of severe disease.Gilead added that the viral enzyme of the coronavirus that remdesivir targets does not contain any additional unique mutations.\"Now with a new version of Omicron (BA.2 subvariant) increasing in circulation around the world, these latest data also suggest that remdesivir will retain antiviral activity against this new subvariant,\" said Tomas Cihlar, senior vice president of virology research at Gilead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":100513015,"gmtCreate":1644670839237,"gmtModify":1663243683242,"authorId":3566982670449095,"author":{"id":3566982670449095,"idStr":"3566982670449095","authorId":3566982670449095,"name":"wywy","avatar":"https://static.tigerbbs.com/76ed86374fc7b16c12094c45ea30787c","vip":2,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.82%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":6,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9092622555,"type":1,"supId":0,"prevId":0,"content":"yea. happy <u>investing</u>","text":"yea. happy <u>investing</u>","html":"yea. happy <u>investing</u>"}],"langContent":"EN"},{"id":9092668913,"gmtCreate":1644622703034,"gmtModify":1676533946476,"author":{"id":"4091758936365950","authorId":"4091758936365950","name":"MHh","avatar":"https://static.tigerbbs.com/54b2feced9ef5dcc9e95997d1f4db280","vip":1,"crmLevel":7,"crmLevelSwitch":1,"idStr":"4091758936365950","authorIdStr":"4091758936365950"},"htmlText":"Drug so expensive! Not cost effective against vaccines, not considering the mortality or morbidity risk with infection","listText":"Drug so expensive! Not cost effective against vaccines, not considering the mortality or morbidity risk with infection","text":"Drug so expensive! Not cost effective against vaccines, not considering the mortality or morbidity risk with infection","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9092668913","repostId":1128194114,"repostType":4,"repost":{"id":"1128194114","kind":"news","pubTimestamp":1644588396,"share":"https://ttm.financial/m/news/1128194114?lang=&edition=full_marsco","pubTime":"2022-02-11 22:06","market":"us","language":"en","title":"Gilead Says Covid Drug Remdesivir Shows Antiviral Activity against Omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=1128194114","media":"Yahoo Finance","summary":"(Reuters) - Gilead Sciences Inc's drug, remdesivir, showed antiviral activity against Omicron, Delta","content":"<html><head></head><body><p>(Reuters) - <a href=\"https://laohu8.com/S/GILD\">Gilead Sciences Inc</a>&#39;s drug, remdesivir, showed antiviral activity against Omicron, Delta and other variants of the coronavirus in laboratory studies, the company said on Friday.</p><p>The study results showed similar activity of remdesivir against the variants and an early ancestral strain of the virus detected in Seattle, Washington, Gilead said.</p><p>Remdesivir, marketed as Veklury, was approved by the FDA in October 2020 to treat hospitalized COVID-19 patients. Last month, this was expanded to non-hospitalized patients who were at high risk of severe disease.</p><p>Gilead added that the viral enzyme of the coronavirus that remdesivir targets does not contain any additional unique mutations.</p><p>&#34;Now with a new version of Omicron (BA.2 subvariant) increasing in circulation around the world, these latest data also suggest that remdesivir will retain antiviral activity against this new subvariant,&#34; said Tomas Cihlar, senior vice president of virology research at Gilead.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Says Covid Drug Remdesivir Shows Antiviral Activity against Omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Says Covid Drug Remdesivir Shows Antiviral Activity against Omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-11 22:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/gilead-says-covid-drug-remdesivir-135752475.html><strong>Yahoo Finance</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) - Gilead Sciences Inc's drug, remdesivir, showed antiviral activity against Omicron, Delta and other variants of the coronavirus in laboratory studies, the company said on Friday.The study ...</p>\n\n<a href=\"https://finance.yahoo.com/news/gilead-says-covid-drug-remdesivir-135752475.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学"},"source_url":"https://finance.yahoo.com/news/gilead-says-covid-drug-remdesivir-135752475.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128194114","content_text":"(Reuters) - Gilead Sciences Inc's drug, remdesivir, showed antiviral activity against Omicron, Delta and other variants of the coronavirus in laboratory studies, the company said on Friday.The study results showed similar activity of remdesivir against the variants and an early ancestral strain of the virus detected in Seattle, Washington, Gilead said.Remdesivir, marketed as Veklury, was approved by the FDA in October 2020 to treat hospitalized COVID-19 patients. Last month, this was expanded to non-hospitalized patients who were at high risk of severe disease.Gilead added that the viral enzyme of the coronavirus that remdesivir targets does not contain any additional unique mutations.\"Now with a new version of Omicron (BA.2 subvariant) increasing in circulation around the world, these latest data also suggest that remdesivir will retain antiviral activity against this new subvariant,\" said Tomas Cihlar, senior vice president of virology research at Gilead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9092686106,"gmtCreate":1644620965236,"gmtModify":1676533946188,"author":{"id":"4098445225447010","authorId":"4098445225447010","name":"Ah Deck","avatar":"https://static.tigerbbs.com/0e52eb1e14e0f630d24f1687ea546cd8","vip":1,"crmLevel":2,"crmLevelSwitch":1,"idStr":"4098445225447010","authorIdStr":"4098445225447010"},"htmlText":"Hope we do not need to take 4th jab 😤..plslike&nbsp;","listText":"Hope we do not need to take 4th jab 😤..plslike&nbsp;","text":"Hope we do not need to take 4th jab 😤..plslike","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9092686106","repostId":1128194114,"repostType":4,"repost":{"id":"1128194114","kind":"news","pubTimestamp":1644588396,"share":"https://ttm.financial/m/news/1128194114?lang=&edition=full_marsco","pubTime":"2022-02-11 22:06","market":"us","language":"en","title":"Gilead Says Covid Drug Remdesivir Shows Antiviral Activity against Omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=1128194114","media":"Yahoo Finance","summary":"(Reuters) - Gilead Sciences Inc's drug, remdesivir, showed antiviral activity against Omicron, Delta","content":"<html><head></head><body><p>(Reuters) - <a href=\"https://laohu8.com/S/GILD\">Gilead Sciences Inc</a>&#39;s drug, remdesivir, showed antiviral activity against Omicron, Delta and other variants of the coronavirus in laboratory studies, the company said on Friday.</p><p>The study results showed similar activity of remdesivir against the variants and an early ancestral strain of the virus detected in Seattle, Washington, Gilead said.</p><p>Remdesivir, marketed as Veklury, was approved by the FDA in October 2020 to treat hospitalized COVID-19 patients. Last month, this was expanded to non-hospitalized patients who were at high risk of severe disease.</p><p>Gilead added that the viral enzyme of the coronavirus that remdesivir targets does not contain any additional unique mutations.</p><p>&#34;Now with a new version of Omicron (BA.2 subvariant) increasing in circulation around the world, these latest data also suggest that remdesivir will retain antiviral activity against this new subvariant,&#34; said Tomas Cihlar, senior vice president of virology research at Gilead.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Says Covid Drug Remdesivir Shows Antiviral Activity against Omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Says Covid Drug Remdesivir Shows Antiviral Activity against Omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-11 22:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/gilead-says-covid-drug-remdesivir-135752475.html><strong>Yahoo Finance</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) - Gilead Sciences Inc's drug, remdesivir, showed antiviral activity against Omicron, Delta and other variants of the coronavirus in laboratory studies, the company said on Friday.The study ...</p>\n\n<a href=\"https://finance.yahoo.com/news/gilead-says-covid-drug-remdesivir-135752475.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学"},"source_url":"https://finance.yahoo.com/news/gilead-says-covid-drug-remdesivir-135752475.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128194114","content_text":"(Reuters) - Gilead Sciences Inc's drug, remdesivir, showed antiviral activity against Omicron, Delta and other variants of the coronavirus in laboratory studies, the company said on Friday.The study results showed similar activity of remdesivir against the variants and an early ancestral strain of the virus detected in Seattle, Washington, Gilead said.Remdesivir, marketed as Veklury, was approved by the FDA in October 2020 to treat hospitalized COVID-19 patients. Last month, this was expanded to non-hospitalized patients who were at high risk of severe disease.Gilead added that the viral enzyme of the coronavirus that remdesivir targets does not contain any additional unique mutations.\"Now with a new version of Omicron (BA.2 subvariant) increasing in circulation around the world, these latest data also suggest that remdesivir will retain antiviral activity against this new subvariant,\" said Tomas Cihlar, senior vice president of virology research at Gilead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9092851026,"gmtCreate":1644590843105,"gmtModify":1676533944269,"author":{"id":"3580355518655832","authorId":"3580355518655832","name":"JohanS","avatar":"https://static.tigerbbs.com/7c3306f813d95dcae72b1f66b0a543c1","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":5,"crmLevelSwitch":1,"idStr":"3580355518655832","authorIdStr":"3580355518655832"},"htmlText":"Nice please like","listText":"Nice please like","text":"Nice please like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9092851026","repostId":1128194114,"repostType":4,"repost":{"id":"1128194114","kind":"news","pubTimestamp":1644588396,"share":"https://ttm.financial/m/news/1128194114?lang=&edition=full_marsco","pubTime":"2022-02-11 22:06","market":"us","language":"en","title":"Gilead Says Covid Drug Remdesivir Shows Antiviral Activity against Omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=1128194114","media":"Yahoo Finance","summary":"(Reuters) - Gilead Sciences Inc's drug, remdesivir, showed antiviral activity against Omicron, Delta","content":"<html><head></head><body><p>(Reuters) - <a href=\"https://laohu8.com/S/GILD\">Gilead Sciences Inc</a>&#39;s drug, remdesivir, showed antiviral activity against Omicron, Delta and other variants of the coronavirus in laboratory studies, the company said on Friday.</p><p>The study results showed similar activity of remdesivir against the variants and an early ancestral strain of the virus detected in Seattle, Washington, Gilead said.</p><p>Remdesivir, marketed as Veklury, was approved by the FDA in October 2020 to treat hospitalized COVID-19 patients. Last month, this was expanded to non-hospitalized patients who were at high risk of severe disease.</p><p>Gilead added that the viral enzyme of the coronavirus that remdesivir targets does not contain any additional unique mutations.</p><p>&#34;Now with a new version of Omicron (BA.2 subvariant) increasing in circulation around the world, these latest data also suggest that remdesivir will retain antiviral activity against this new subvariant,&#34; said Tomas Cihlar, senior vice president of virology research at Gilead.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Says Covid Drug Remdesivir Shows Antiviral Activity against Omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Says Covid Drug Remdesivir Shows Antiviral Activity against Omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-11 22:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/gilead-says-covid-drug-remdesivir-135752475.html><strong>Yahoo Finance</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) - Gilead Sciences Inc's drug, remdesivir, showed antiviral activity against Omicron, Delta and other variants of the coronavirus in laboratory studies, the company said on Friday.The study ...</p>\n\n<a href=\"https://finance.yahoo.com/news/gilead-says-covid-drug-remdesivir-135752475.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学"},"source_url":"https://finance.yahoo.com/news/gilead-says-covid-drug-remdesivir-135752475.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128194114","content_text":"(Reuters) - Gilead Sciences Inc's drug, remdesivir, showed antiviral activity against Omicron, Delta and other variants of the coronavirus in laboratory studies, the company said on Friday.The study results showed similar activity of remdesivir against the variants and an early ancestral strain of the virus detected in Seattle, Washington, Gilead said.Remdesivir, marketed as Veklury, was approved by the FDA in October 2020 to treat hospitalized COVID-19 patients. Last month, this was expanded to non-hospitalized patients who were at high risk of severe disease.Gilead added that the viral enzyme of the coronavirus that remdesivir targets does not contain any additional unique mutations.\"Now with a new version of Omicron (BA.2 subvariant) increasing in circulation around the world, these latest data also suggest that remdesivir will retain antiviral activity against this new subvariant,\" said Tomas Cihlar, senior vice president of virology research at Gilead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":100503699,"gmtCreate":1644594469846,"gmtModify":1663243639045,"authorId":3565581801642914,"author":{"id":3565581801642914,"idStr":"3565581801642914","authorId":3565581801642914,"name":"Meeooww","avatar":"https://community-static.tradeup.com/news/4e96aeba8e0507542c492dab07ea2828","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9092851026,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"EN"},{"id":9092853174,"gmtCreate":1644590714601,"gmtModify":1676533944244,"author":{"id":"3581742924827239","authorId":"3581742924827239","name":"JiaocyTi","avatar":"https://static.tigerbbs.com/c16d760078e396b46033bc97afede0c8","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3581742924827239","authorIdStr":"3581742924827239"},"htmlText":"23","listText":"23","text":"23","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9092853174","repostId":1128194114,"repostType":4,"repost":{"id":"1128194114","kind":"news","pubTimestamp":1644588396,"share":"https://ttm.financial/m/news/1128194114?lang=&edition=full_marsco","pubTime":"2022-02-11 22:06","market":"us","language":"en","title":"Gilead Says Covid Drug Remdesivir Shows Antiviral Activity against Omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=1128194114","media":"Yahoo Finance","summary":"(Reuters) - Gilead Sciences Inc's drug, remdesivir, showed antiviral activity against Omicron, Delta","content":"<html><head></head><body><p>(Reuters) - <a href=\"https://laohu8.com/S/GILD\">Gilead Sciences Inc</a>&#39;s drug, remdesivir, showed antiviral activity against Omicron, Delta and other variants of the coronavirus in laboratory studies, the company said on Friday.</p><p>The study results showed similar activity of remdesivir against the variants and an early ancestral strain of the virus detected in Seattle, Washington, Gilead said.</p><p>Remdesivir, marketed as Veklury, was approved by the FDA in October 2020 to treat hospitalized COVID-19 patients. Last month, this was expanded to non-hospitalized patients who were at high risk of severe disease.</p><p>Gilead added that the viral enzyme of the coronavirus that remdesivir targets does not contain any additional unique mutations.</p><p>&#34;Now with a new version of Omicron (BA.2 subvariant) increasing in circulation around the world, these latest data also suggest that remdesivir will retain antiviral activity against this new subvariant,&#34; said Tomas Cihlar, senior vice president of virology research at Gilead.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Says Covid Drug Remdesivir Shows Antiviral Activity against Omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Says Covid Drug Remdesivir Shows Antiviral Activity against Omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-11 22:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/gilead-says-covid-drug-remdesivir-135752475.html><strong>Yahoo Finance</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) - Gilead Sciences Inc's drug, remdesivir, showed antiviral activity against Omicron, Delta and other variants of the coronavirus in laboratory studies, the company said on Friday.The study ...</p>\n\n<a href=\"https://finance.yahoo.com/news/gilead-says-covid-drug-remdesivir-135752475.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学"},"source_url":"https://finance.yahoo.com/news/gilead-says-covid-drug-remdesivir-135752475.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128194114","content_text":"(Reuters) - Gilead Sciences Inc's drug, remdesivir, showed antiviral activity against Omicron, Delta and other variants of the coronavirus in laboratory studies, the company said on Friday.The study results showed similar activity of remdesivir against the variants and an early ancestral strain of the virus detected in Seattle, Washington, Gilead said.Remdesivir, marketed as Veklury, was approved by the FDA in October 2020 to treat hospitalized COVID-19 patients. Last month, this was expanded to non-hospitalized patients who were at high risk of severe disease.Gilead added that the viral enzyme of the coronavirus that remdesivir targets does not contain any additional unique mutations.\"Now with a new version of Omicron (BA.2 subvariant) increasing in circulation around the world, these latest data also suggest that remdesivir will retain antiviral activity against this new subvariant,\" said Tomas Cihlar, senior vice president of virology research at Gilead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":100503040,"gmtCreate":1644590729893,"gmtModify":1663243635537,"authorId":3581742924827239,"author":{"id":3581742924827239,"idStr":"3581742924827239","authorId":3581742924827239,"name":"JiaocyTi","avatar":"https://static.tigerbbs.com/c16d760078e396b46033bc97afede0c8","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9092853174,"type":1,"supId":0,"prevId":0,"content":"<u>123</u>","text":"<u>123</u>","html":"<u>123</u>"}],"langContent":"EN"},{"id":9092828207,"gmtCreate":1644589651707,"gmtModify":1676533944073,"author":{"id":"3586590970630142","authorId":"3586590970630142","name":"zero79","avatar":"https://static.tigerbbs.com/18bdafe6e77141b002b8ed62dd5cc0e3","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3586590970630142","authorIdStr":"3586590970630142"},"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9092828207","repostId":1128194114,"repostType":4,"repost":{"id":"1128194114","kind":"news","pubTimestamp":1644588396,"share":"https://ttm.financial/m/news/1128194114?lang=&edition=full_marsco","pubTime":"2022-02-11 22:06","market":"us","language":"en","title":"Gilead Says Covid Drug Remdesivir Shows Antiviral Activity against Omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=1128194114","media":"Yahoo Finance","summary":"(Reuters) - Gilead Sciences Inc's drug, remdesivir, showed antiviral activity against Omicron, Delta","content":"<html><head></head><body><p>(Reuters) - <a href=\"https://laohu8.com/S/GILD\">Gilead Sciences Inc</a>&#39;s drug, remdesivir, showed antiviral activity against Omicron, Delta and other variants of the coronavirus in laboratory studies, the company said on Friday.</p><p>The study results showed similar activity of remdesivir against the variants and an early ancestral strain of the virus detected in Seattle, Washington, Gilead said.</p><p>Remdesivir, marketed as Veklury, was approved by the FDA in October 2020 to treat hospitalized COVID-19 patients. Last month, this was expanded to non-hospitalized patients who were at high risk of severe disease.</p><p>Gilead added that the viral enzyme of the coronavirus that remdesivir targets does not contain any additional unique mutations.</p><p>&#34;Now with a new version of Omicron (BA.2 subvariant) increasing in circulation around the world, these latest data also suggest that remdesivir will retain antiviral activity against this new subvariant,&#34; said Tomas Cihlar, senior vice president of virology research at Gilead.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Says Covid Drug Remdesivir Shows Antiviral Activity against Omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Says Covid Drug Remdesivir Shows Antiviral Activity against Omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-11 22:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/gilead-says-covid-drug-remdesivir-135752475.html><strong>Yahoo Finance</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) - Gilead Sciences Inc's drug, remdesivir, showed antiviral activity against Omicron, Delta and other variants of the coronavirus in laboratory studies, the company said on Friday.The study ...</p>\n\n<a href=\"https://finance.yahoo.com/news/gilead-says-covid-drug-remdesivir-135752475.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学"},"source_url":"https://finance.yahoo.com/news/gilead-says-covid-drug-remdesivir-135752475.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128194114","content_text":"(Reuters) - Gilead Sciences Inc's drug, remdesivir, showed antiviral activity against Omicron, Delta and other variants of the coronavirus in laboratory studies, the company said on Friday.The study results showed similar activity of remdesivir against the variants and an early ancestral strain of the virus detected in Seattle, Washington, Gilead said.Remdesivir, marketed as Veklury, was approved by the FDA in October 2020 to treat hospitalized COVID-19 patients. Last month, this was expanded to non-hospitalized patients who were at high risk of severe disease.Gilead added that the viral enzyme of the coronavirus that remdesivir targets does not contain any additional unique mutations.\"Now with a new version of Omicron (BA.2 subvariant) increasing in circulation around the world, these latest data also suggest that remdesivir will retain antiviral activity against this new subvariant,\" said Tomas Cihlar, senior vice president of virology research at Gilead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":100502896,"gmtCreate":1644590022710,"gmtModify":1663243635749,"authorId":3581166585496611,"author":{"id":3581166585496611,"idStr":"3581166585496611","authorId":3581166585496611,"name":"ATJS","avatar":"https://static.tigerbbs.com/dedee9b81a49fe29e1cade245c54c758","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9092828207,"type":1,"supId":0,"prevId":0,"content":"yeah","text":"yeah","html":"yeah"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":103,"commentSize":8,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}